Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease
Authors:
- Michele MalagolaMMMichele Malagola
- Valeria CancelliVCValeria Cancelli
- Cristina SkertCSCristina Skert
- Pierino Ferremi LealiPLPierino Ferremi Leali
- Emilio FerrariEFEmilio Ferrari
- Alessandra TiburziATAlessandra Tiburzi
- Maria Luisa SalaMSMaria Luisa Sala
- Irene DonniniIDIrene Donnini
- Patrizia ChiusoloPCPatrizia Chiusolo
- Alberto MussettiAMAlberto Mussetti
- Marta BattistaMBMarta Battista
- Alessandro TurraATAlessandro Turra
- 1 December 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (12) , e147-e155
Abstract
Extracorporeal photopheresis (ECP) is considered a valid second-line treatment for acute and chronic graft versus host disease (GVHD). Ninety-four patients with acute GVHD (aGVHD) (n = 45) and chronic GVHD (cGVHD) (n = 49), retrospectively recruited in 6 Italian centers, were submitted to ECP for second-line treatment. At the time of ECP, 22 (49%) and 23 (51%) of 45 patients with aGHVD were nonresponsive and in partial remission (PR) after steroids, respectively, and all the 49 patients with cGVHD were steroid refractory. Forty-one (91%) of 45 patients with aGVHD achieved complete remission (CR) after ECP. Fifteen (33%) of 45 patients developed cGVHD. The CR rate in patients who started ECP being nonresponsive and in PR after steroid was 86% and 96%, respectively. After a median follow-up of 20 months (range, 2-72), 15 (33%) of 45 patients developed cGHVD and 16 (35%) of 45 patients died, in 3 cases for aGVHD. A trend for a better survival was seen among patients who started ECP in PR after steroid (80% vs 50% at 2 years; P = 0.07). Overall, 22 (45%) of 49 patients and 17 (35%) of 49 patients with steroid refractory cGHVD achieved CR and PR after ECP, respectively. After a median follow-up of 27 months, 44 (90%) of 49 patients are alive, 21 of whom (48%) are on steroid. Extracorporeal photopheresis is confirmed as an effective second-line treatment in both aGVHD and cGVHD, because it can induce a response in more than 80% of the patients and a long-term survival in at least 50% of the cases.Keywords
This publication has 39 references indexed in Scilit:
- Graft-versus-host diseaseThe Lancet, 2009
- Novel approaches to the therapy of steroid-resistant acute graft-versus-host diseaseTransplantation and Cellular Therapy, 2004
- Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of responseBlood, 2003
- Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and resultsBone Marrow Transplantation, 2003
- Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone aloneBlood, 2002
- Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot studyBlood, 2000
- Successful Use of Extracorporeal Photochemotherapy in the Treatment of Severe Acute and Chronic Graft-Versus-Host DiseaseBlood, 1998
- Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host diseaseTransplantation and Cellular Therapy, 1998
- A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatmentBlood, 1991
- A retrospective analysis of therapy for acute graft-versus-host disease: initial treatmentBlood, 1990